Lava Therapeutics reports Q2 EPS (48c), consensus (47c)

“We are focused on driving forward our lead program, LAVA-1207 in patients with mCRPC and are pleased our Gammabody platform continues to receive the support of investigators and patients as enrollment remains on track. In addition, we are pleased with the progress of our partnered programs providing additional validation as well as extending our cash runway,” said Steve Hurly, president and chief executive officer of LAVA. “We remain well-positioned to bring meaningful benefits to patients in areas of high unmet need and deliver shareholder value.”